Tesla rises after leading Morgan Stanley's auto picks on AI potential
** Tesla's TSLA.O shares rise 3.2% premarket to $302.31
** Brokerage Morgan Stanley reinstates Tesla as their "top pick" in US Automotive sector, setting a $430 price target that implies over 50% upside, with a bull case scenario of $800
** "Tesla's softer auto deliveries are emblematic of a
company in the transition from an automotive 'pure play' to a highly diversified play on AI and robotics," brokerage says
** Co's future value lies in its expansion into AI, robotics, energy storage, and autonomous vehicles- brokerage
** Despite TSLA's significant stock price decline and potential delivery challenges in 2025, the brokerage sees this as a good opportunity to invest, primarily due to TSLA's position in the embodied AI sector rather than just its automotive business
** As of last close, TSLA has fallen 27.5% in 2025
Related Articles
BoE August Rate Decision Commentary: Where Next for the Pound?
TradingKey - On 7 August 2025, the Bank of England (BoE) lowered its benchmark interest rate from 4.25% to 4%, aligning with broad market expectations. Notably, the decision sparked significant division within the committee, requiring two rounds of voting to pass.
MP Materials 2Q25 Earnings Comment: Going up the Value Chain
TradingKey - MP Materials released its earnings for the second quarter of the fiscal 2025 on August 7th after the bell.The smaller loss and the better revenue were surely welcomed by investors, and the stock is up 8.50% in the post-bell session.
Eli Lilly’s Q2 2025 Triumph: Soaring Revenue, Plunging Stock – What’s Behind the Paradox?
TradingKey - Eli Lilly released its Q2 2025 financial results, demonstrating impressive financial performance. However, despite the stellar results, its stock price plummeted by over 14%, closing at approximately $640, down more than 30% from its yearly high..jpg)
Caution on Short-Term Downside Risks for U.S. Stock Market
TradingKey - Last Friday, the U.S. Labor Department sharply revised downward its May and June nonfarm payroll figures by a combined 258,000 jobs, a reduction exceeding 90%. Meanwhile, July’s payroll increase came in at just 73,000, falling short of the 100,000 forecast.
From Ozempic to Wegovy: Growth and Risks Behind Novo Nordisk’s Q2 Performance
TradingKey - Novo Nordisk achieved revenue of $11.67 billion in Q2 of the 2025 fiscal year, a 19% increase year-over-year, but it fell short of market expectations. Growth was primarily driven by strong performance in obesity care and rare diseases.
